Pharma Supply Chain Experts on Gray Market Peptide Distribution

Why do peptide manufacturers allow gray market distribution instead of going legitimate? Working on research about peptide supply chains and noticed something weird. Companies like have official distribution everywhere except certain markets (like UAE/Dubai), but their products still end up there through unofficial resellers who aren’t properly licensed. From a business perspective, this doesn’t make sense to me. If there’s demand and people are buying anyway, why not just establish proper distribution? The markup through multiple middlemen must be insane, and quality control gets sketchy. Is this a deliberate strategy? Like maybe it’s easier to let gray market guys deal with regulatory headaches while focusing on easier markets? Anyone in pharma/biotech know why companies would prefer this over legitimate market entry? Seems like they’re leaving money on the table and creating liability issues. This is academic research on supply chain strategies - not looking for sourcing advice, just trying to understand the business logic.